Aktuellt
SENASTE
Fluoguide reported slightly higher costs in Q4 than we expected, but the clinical programme remains on track for now, and Fluoguide has sufficient cash to fund operations through 2024. Management has issued guidance for operational and strategic KPIs, including to partner FG001. We expect 2024 to be an exciting year for Fluoguide. We reiterate our SEK 173-188 per share equity valuation range.
LÄS MER
